Waldencast (NASDAQ:WALD) Receives New Coverage from Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Waldencast (NASDAQ:WALDFree Report) in a report released on Friday, MarketBeat reports. The firm issued a buy rating and a $5.00 price objective on the stock.

WALD has been the topic of a number of other research reports. DA Davidson upped their price target on shares of Waldencast from $6.50 to $7.25 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Canaccord Genuity Group started coverage on shares of Waldencast in a research report on Friday. They set a “buy” rating and a $5.00 price target on the stock. Finally, Telsey Advisory Group reaffirmed an “outperform” rating and set a $6.00 price target on shares of Waldencast in a research report on Wednesday, October 9th.

Check Out Our Latest Report on WALD

Waldencast Price Performance

NASDAQ WALD opened at $3.85 on Friday. Waldencast has a twelve month low of $2.40 and a twelve month high of $12.00. The stock has a fifty day simple moving average of $3.56 and a 200 day simple moving average of $3.87. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.78 and a current ratio of 1.47.

Hedge Funds Weigh In On Waldencast

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of Waldencast in the 2nd quarter worth about $37,000. Catalina Capital Group LLC acquired a new stake in shares of Waldencast in the 1st quarter worth about $73,000. Norden Group LLC acquired a new stake in shares of Waldencast in the 1st quarter worth about $92,000. McAdam LLC acquired a new stake in shares of Waldencast in the 3rd quarter worth about $62,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Waldencast in the 1st quarter worth about $142,000. Institutional investors own 41.97% of the company’s stock.

About Waldencast

(Get Free Report)

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.

Recommended Stories

Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.